H19: A Regulatory Biomarker with Prognostic Value in Leukemias

Objective & Hypothesis:There are pieces of evidence indicating the important role of long noncoding RNAs (lncRNA) with transcription factors and their effect on gene expression at transcription and epigenetic levels.

📊

Key Findings & Data:The possible role of lncRNAs in humans have been investigated the involvement of H19 in cancers, including leukemia.

💡

Conclusion & Impact:In this review, the probable regulatory role of H19 as a prognostic biomarker with a variable role dependent upon disease context will be discussed.

🔬Design:Review & Systematic Survey

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Özet

There are pieces of evidence indicating the important role of long noncoding RNAs (lncRNA) with transcription factors and their effect on gene expression at transcription and epigenetic levels. The possible role of lncRNAs in humans have been investigated the involvement of H19 in cancers, including leukemia. H19 inhibits the transcription of IGF2 receptor via miR-675 and thereby regulates IGF-2 signaling. In chronic myeloproliferative disorders (CMPD), bone marrow cells of patients express H19 in significantly lower levels than healthy samples, and the reduced expression of H19 through IGF-2 reinforces the growth signal. H19 plays a regulatory role in maintaining the proliferation and selfrenewal abilities of HSCs. This molecule also influences the pathogenesis of leukemia due to its role in increasing the proliferation and regulating the quiescence of stem cells. Accordingly, it may be possible to consider H19 as a prognostic biomarker for myeloid disorders. In this review, the probable regulatory role of H19 as a prognostic biomarker with a variable role dependent upon disease context will be discussed.

🔖

Cite This Article

GHANAVAT, M., KHODADİ, E., PEZESHKI, S. M. S., SHAHJAHANİ, M., SHAHRABİ, S. (2019). H19: A Regulatory Biomarker with Prognostic Value in Leukemias. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 4, 246–250. https://ajindex.com/articles/125647

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Chen S, Liang H, Yang H, Zhou K, Xu L, Liu J, et al. Long noncoding RNAs: The novel diagnostic biomarkers for leukemia. Environmental toxicology and pharmacology 2017;55:81–6. 2. Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. Cancer genetics 2017;216:105–10. 3. He H, Wang N, Yi X, Tang C, Wang D. Long non-coding RNA H19 regulates E2F1 expression by competitively sponging endogenous miR-29a-3p in clear cell renal cell carcinoma. Cell & Bioscience 2017;7:65. 4. Li H, Li J, Jia S, Wu M, An J, Zheng Q, et al. miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer. Oncotarget 2015;6:31958. 5. Zhang E-B, Han L, Yin D-D, Kong R, De W, Chen J. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Medical oncology 2014;31:914. 6. Alvarez-Dominguez JR, Hu W, Gromatzky AA, Lodish HF. Long noncoding RNAs during normal and malignant hematopoiesis. International journal of hematology 2014;99:531–41. 7. Jarroux J, Morillon A, Pinskaya M. History, Discovery, and classification of lncRNAs. Long Non Coding RNA Biology: Springer; 2017;1–46. 8. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 2014;5:2318. 9. Shahjahani M, Khodadi E, Seghatoleslami M, Asl JM, Golchin N, Zaieri ZD, Saki N. Rare cytogenetic abnormalities and alteration of microRNAs in acute myeloid leukemia and response to therapy. Oncology reviews 2015;10;9. 10. Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 2014;1839:1097–109. 11. Tessema M, Länger F, Bock O, Seltsam A, Metzig K, Hasemeier B, et al. Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. International journal of oncology 2005;26:499–507. 12. Zhou Jd, Lin J, Zhang Tj, Ma Jc, Li Xx, Wen Xm, et al. Hypomethylation‐mediated H19 overexpression increases the risk of disease evolution through the association with BCR‐ ABL transcript in chronic myeloid leukemia. Journal of cellular physiology. 2017. 13. Bock O, Schlue J, Kreipe H. Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders. Leukemia 2003;17:815. 14. Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan L, et al. High expression of long non‐coding RNA H19 is required for eff